Hypoalbuminemia is a common finding and independent predictor for unfavorable prognosis.
| INTRODUCTION
Hypoalbuminemia, defined as a decreased serum concentration of albumin (<35 g/L) in adults, is a common finding and independent predictor for adverse prognosis among hospitalized patients. 1, 2 Although the pathophysiology remains uncertain, it has been postulated that the catabolism and metabolism of albumin may be increased under acute stress or critical illness, thereby affecting its biological functions. 3 Low albumin may also reflect inflammation, poor nutritional status, or underlying liver or kidney disease that adversely impacts the clinical outcome. 4 Previous studies of population-based cohorts demonstrate that low circulatory albumin concentration is inversely related to a longterm risk of venous thromboembolism (VTE). [5] [6] [7] [8] We now report the association of baseline plasma albumin with VTE among hospitalized medically ill patients randomized in the Acute Medically Ill VTE Prevention with Extended Duration Betrixaban (APEX) Trial. 9 We tested
Abbreviations: APEX, Acute Medically Ill VTE Prevention with Extended Duration Betrixaban trial; CRP, C-reactive protein; DVT, deep vein thrombosis; PE, pulmonary embolism; ULN, upper limit of normal; VTE, venous thromboembolism.
the hypothesis that hypoalbuminemic patients would have a greater short-term risk of developing VTE through the end of study at 77 days. We also investigated the additive prognostic value of albumin measurement in conjunction with validated VTE risk assessment tools.
2 | METHODS
| The APEX trial and endpoints
The design and rationale for the APEX trial have been described in detail previously. 10 In brief, APEX trial was a multicenter, double-blind, Events were adjudicated by an independent clinical events committee blinded to thromboprophylaxis allocation. All randomized patients with non-missing baseline albumin measurements and evaluable VTE endpoints (N = 7266) were included in the analysis.
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.
| Statistical analysis
Analyses in this substudy were post hoc and exploratory. 14, 15 Specifically, risk discrimination was evaluated by the change in area under the receiver-operating-characteristic curve (ΔAUC) and integrated discrimination improvement (IDI). Risk reclassification was evaluated by category-free net reclassification improvement (NRI). 16 All analyses were performed with the SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA).
3 | RESULTS
| Baseline characteristics
The median albumin concentration was 39 g/L (25th percentile: 35 g/ L; 75th percentile: 42 g/L). Accordingly, patients were divided by albumin quartiles as follows:
There was no significant imbalance across albumin quartiles with respect to the duration of hospitalization (P = .10), use of intermittent pneumatic compression (P = .10), thromboprophylaxis allocation (P = .49), and VTE risk factors including history of previous VTE (P = .25), known thrombophilia (P = .73), current lower-limb paralysis (P = .10), malignancy (P = .08), intensive care unit admission (P = .19),
and age >60 years (P = .41) ( Table 1) . Notably, patients in the lowest albumin quartile (<35 g/L) had a lower BMI, more infection as the index hospitalization event, and higher baseline levels of D-dimer and CRP compared with other groups. Pneumonia, urinary tract infection, and sepsis occurred in 50.8%, 14.2%, and 1.0% of patients who were admitted with an acute infection (Supporting Information Table S1 ).
Patients in the lowest albumin quartile (<35 g/L) had a higher percentage of cellulitis (9.3%), urinary tract infection (16.9%), and combined infections (6.2%) compared with other groups.
| Baseline albumin in relation to VTE incidence at 77 days
The incidence of VTE at 77 days across baseline albumin categories (as an ordinal variable in 5 g/L increments) is illustrated in Supporting
Information Figure S1 . A stepwise increase in the rate of VTE was observed toward the lower albumin category (P for trend <.0001).
Patients with baseline albumin of <25 and ≥25 to <30 g/L had the highest 77-day rate of VTE (19.57% and 12.28%, respectively), whereas patients with albumin of ≥40 to <45 and ≥45 g/L had the lowest rate (5.43% and 3.61%, respectively). The relation of albumin to VTE was examined by fitting the restricted cubic spline model (Figure 1 ), which suggested an inverse dose-dependent relationship between albumin and the odds ratio for VTE.
| Association of VTE endpoints to albumin
The association between albumin and VTE endpoints (composite as well as its components) was assessed by fitting the logistic regression models ( The risks of VTE and its components were compared between two treatment groups in patients with low baseline albumin (<35 g/L)
as well as those with normal baseline albumin (≥35 g/L) (Supporting Information Table S2 ). Among hypoalbuminemic patients, betrixaban group had a numerically but not significantly lower rate of VTE com- 
| Association of VTE endpoints to albumin in propensity score-matched cohort
Propensity score-matched analysis was performed to further examine the association of VTE to hypoalbuminemia (Table 3 and Supporting Information 
| Refinement of VTE risk prediction by albumin
The incremental prognostic value of albumin was examined by adding albumin to two validated VTE risk assessment models: International
Medical Prevention Registry on Venous Thromboembolism Despite anticoagulation with extended-duration betrixaban or standard-duration enoxaparin, the risk of breakthrough VTE at 77 days was higher in the low albumin group (betrixaban vs enoxaparin: 7.79% vs 10.27%) than the normal albumin group (betrixaban vs enoxaparin: 4.41% vs 6.39%). Although a significant VTE reduction by betrixaban was not observed in the hypoalbuminemic patients, it is noteworthy that albumin category did not significantly modify the effect of thromboprophylaxis (P for interaction = .70). The lack of statistical significance in preventing VTE among hypoalbuminemic patients may be attributable to the inadequate sample size (approximately one third of the group with normal albumin levels). As acutely Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; OR, odds ratio; PE, pulmonary embolism; SD, SD; VTE, venous thromboembolism. a Model 1 examines the univariate association between albumin per quartile and VTE endpoint. b Model 2 is adjusted for age (as continuous), sex, race, body mass index (as continuous), creatinine clearance (as categorical), acute medical condition, mechanical prophylaxis, pharmacological prophylaxis, D-dimer (as continuous), and C-reactive protein (as continuous). c The occurrence of asymptomatic DVT was assessed by protocol-mandated compression ultrasound between 35 and 42 days in all randomized patients regardless of discontinuation or interruption of study medications.
ill hospitalized patients represent a population with a heterogeneous predisposition to VTE, 17 this finding indicates that albumin should not be considered as the stand-alone tool for identifying patient subsets that would benefit from extended-duration prophylaxis.
Previous studies have described the link between albumin and a modest long-term risk of venous thromboembolism. [5] [6] [7] The present analysis extends the previous findings and demonstrates that a hypoalbuminemic state identified at hospitalization was associated with a greater VTE risk through 77 days after adjusting for potential confounders, thromboprophylaxis provision, and biomarkers for fibrinolysis (ie, D-dimer) and inflammation (ie, CRP). Several explanations have been proposed to explain the relationship between low albumin and increased thrombotic risks. First, albumin was found to have anticoagulant properties by inhibiting fibrin polymerization and platelet aggregation. 18, 19 In addition, albumin appears to exert a heparin-like action by enhancing the effect of antithrombin III. 20 Second, as a negative acute-phase reactant, circulatory level of albumin may fall as a result of increased transcapillary leakage or reduced hepatic synthesis mediated by inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha. [21] [22] [23] Consequently, hypoalbuminemia may indicate a hyperinflammatory status that contributes to the increased incidence of VTE. Third, low albumin levels may reflect the presence of certain disorders such as nephrotic syndrome or chronic kidney disease that are also risk factors for VTE. 8, 24, 25 Last, hypoalbuminemia may promote hepatic synthesis of coagulation factors such as factor V, factor VIII, and fibrinogen as a compensatory response. 26 However, it is noteworthy that results from the current study do not suggest a causal relationship between hypoalbuminemia and VTE.
Instead, these findings support the prognostic value of albumin measurement in VTE risk prediction for medical inpatients.
Several risk assessment models have been developed to identify hospitalized patients at risk of VTE. 14, 15, 17, 27, 28 The present study demonstrated that the addition of albumin to validated risk assessment models (such as the IMPROVE score or Padua score) improved their performance in risk discrimination and reclassification. These findings suggest that laboratory tests or biomarkers may be used in conjunction with risk assessment models comprised of clinical variables to refine VTE prediction. 29 Albumin measurement is widely available and routinely included in the comprehensive metabolic panel of laboratory tests. Low albumin concentration may be considered as an integrative index for inflammation, hypercoagulability, or disease states that predispose patients to thrombosis. Future studies should consider incorporating hypoalbuminemia in the VTE risk assessment tools.
| LIMITATIONS
First, this study is an exploratory analysis from a population that agreed to participate in a clinical trial with specific enrollment criteria.
Albumin measurement was performed at a central laboratory but not locally. Second, only CRP and D-dimer were available in the study population, and we could not fully account for the possible influence of inflammation or hypercoagulability on the association between albumin and VTE. Third, diagnostic studies to ascertain the causes of The occurrence of asymptomatic DVT was assessed by protocol-mandated compression ultrasound between 35 and 42 days in all randomized patients regardless of discontinuation or interruption of study medications.
hypoalbuminemia were not performed. Last, serum levels of albumin may vary with the disease course and have altered at the time of assessment of VTE endpoints.
| CONCLUSIONS
Acutely ill hospitalized patients with low serum albumin at baseline had an increased VTE risk through 77 days. VTE risk assessment models for medical inpatients should consider incorporation of albumin measurement.
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